Compare DTI & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DTI | BYSI |
|---|---|---|
| Founded | 1984 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.0M | 58.4M |
| IPO Year | 2021 | 2016 |
| Metric | DTI | BYSI |
|---|---|---|
| Price | $2.35 | $1.15 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 217.6K | 23.1K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $154,446,000.00 | N/A |
| Revenue This Year | $2.05 | N/A |
| Revenue Next Year | $4.48 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.59 | N/A |
| 52 Week Low | $1.65 | $0.99 |
| 52 Week High | $4.69 | $2.44 |
| Indicator | DTI | BYSI |
|---|---|---|
| Relative Strength Index (RSI) | 49.56 | 36.90 |
| Support Level | $2.16 | $1.18 |
| Resistance Level | $2.34 | $1.60 |
| Average True Range (ATR) | 0.07 | 0.09 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 51.61 | 42.66 |
Drilling Tools International Corp is an oilfield services company that designs, engineers, and manufactures rental-focused tools used in onshore and offshore horizontal and directional drilling operations, as well as solutions across the well life cycle. It operates through two geographic segments: Western Hemisphere and Eastern Hemisphere. The Western Hemisphere, which generates the majority of revenue, provides downhole drilling tools and rental services for onshore and offshore operations across North America and Latin America, supported by service centers in the U.S. and Canada. The Eastern Hemisphere covers Europe, the Middle East, and Asia-Pacific, where the company offers drilling and well lifecycle solutions through international service centers across the EMEA and APAC regions.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multiple therapeutic opportunities.